Sbr Kästner

Untersuchungen über den klinischen Einsatz von Brushite- und Hydroxylapatit-Zement beim Schaf

For future clinical use as synthetic bone replacement, an injectable brushite-(chronOS™-Inject) and hydroxylapatite-(Biobon®) cement were compared in a drill hole model in 10 sheep over time at 2, 4, 6, 8, 16 and 24 weeks. Results were compared regarding their practical use, biocompatibiliy, resorption mechanism and subsequent new bone formation. The cements were filled into drill holes (O 8x13mm) of the proximal and distal humerus, and femur and the samples evaluated macroscopically, radiologically and microscopically including histomorphometrical quantification of percentages of new bone, fibrous tissue and remnants of cements. The cement area decreased continuously from 2 to 24 weeks with chronOS™-Inject, as well as the area of granules. Inversely, the subsequent new bone formation increased from 2-24 weeks accordingly. With Biobon® the cement area decreased slower between 2 and 24 weeks, and the new bone formation was less. Both cements were well integrated into the bone in long bones. chronOS™-Inject demonstrated good biocompatibility and was almost completely replaced through bone within 24 weeks. Biobon® was resorbed considerably slower and initially a slight inflammatory reaction including bone resorption was observed within the adjacent host bone

Pharmacokinetics of recombinant hirudin in healthy horses.

REASONS FOR PERFORMING STUDY Recombinant (r)-hirudin is a specific inhibitor of thrombin that is independent of the activity of antithrombin. OBJECTIVES To evaluate pharmacokinetic properties and coagulatory changes of r-hirudin in healthy horses. METHODS Two clinically healthy horses received a single i.v. bolus of 0.4 mg/kg bwt r-hirudin and 6 clinically healthy horses received the same dose subcutaneously (subcut.) q. 12 h for 3 days. Coagulation times and r-hirudin plasma concentration were determined over 720 mins and 3 days after i.v. and subcut. administration, respectively. RESULTS In all horses, treatment with r-hirudin was not associated with systemic or local side effects. After i.v. injection, the 2 horses showed an elimination half-life of 58 and 80 mins, respectively. After subcut. administration, maximum plasma concentration of r-hirudin occurred at 128 +/- 55 mins and declined with a terminal half-life of 561 +/- 364 mins. Maximum response of activated partial thromboplastin time (aPTT) occurred 1.5 h after administration of r-hirudin. A prolongation of 1.9 +/- 0.2 times the pretreatment value was noted. CONCLUSIONS Pharmacokinetics of r-hirudin in healthy horses were similar to those in man and other animal species. POTENTIAL RELEVANCE The results of this study indicate that r-hirudin can be used in horses, but further studies should be performed in order to prove its effectiveness in diseased horses.

Effect of dexmedetomidine and medetomidine on isoflurane requirements in sheep undergoing orthopaedic surgery

This study compared the anaesthetic sparing and potential hypoxaemic effects of dexmedetomidine and medetomidine, after intravenous administration in sheep.